MX2017008660A - Polipeptidos enlazados a il-17a. - Google Patents

Polipeptidos enlazados a il-17a.

Info

Publication number
MX2017008660A
MX2017008660A MX2017008660A MX2017008660A MX2017008660A MX 2017008660 A MX2017008660 A MX 2017008660A MX 2017008660 A MX2017008660 A MX 2017008660A MX 2017008660 A MX2017008660 A MX 2017008660A MX 2017008660 A MX2017008660 A MX 2017008660A
Authority
MX
Mexico
Prior art keywords
binding polypeptides
interleukin
binding polypeptide
binding
x26lx28x29
Prior art date
Application number
MX2017008660A
Other languages
English (en)
Inventor
Feldwisch Joachim
Frejd Fredrik
GUDMUNDSDOTTER Lindvi
Klint Susanne
Original Assignee
Affibody Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affibody Ab filed Critical Affibody Ab
Publication of MX2017008660A publication Critical patent/MX2017008660A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

La presente descripción se refiere a una clase de polipéptidos preparados por ingeniería que tiene una afinidad de enlace para interleucina-17A (IL-17A), y proporciona un polipéptido enlazado a IL-17A que comprende la secuencia EX2DX4AX6X7EIX10X11LPNL X16X17X18QX20X21AFIX25 X26LX28X29. También se describe el uso de tal polipéptido enlazado a interleucina- 17A corno un agente de diagnóstico, pronóstico y/o terapéutico.
MX2017008660A 2015-01-12 2016-01-12 Polipeptidos enlazados a il-17a. MX2017008660A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15150786 2015-01-12
PCT/EP2016/050456 WO2016113246A1 (en) 2015-01-12 2016-01-12 Il-17a-binding polypeptides

Publications (1)

Publication Number Publication Date
MX2017008660A true MX2017008660A (es) 2017-11-17

Family

ID=52339024

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008660A MX2017008660A (es) 2015-01-12 2016-01-12 Polipeptidos enlazados a il-17a.

Country Status (19)

Country Link
US (2) US10934335B2 (es)
EP (2) EP3738976A1 (es)
JP (3) JP6943764B2 (es)
CN (1) CN108064235A (es)
AU (1) AU2016208161B2 (es)
BR (1) BR112017014559A2 (es)
CA (1) CA2972683A1 (es)
DK (1) DK3245224T3 (es)
ES (1) ES2822431T3 (es)
HU (1) HUE052121T2 (es)
IL (1) IL253004B (es)
MX (1) MX2017008660A (es)
MY (1) MY188784A (es)
NZ (1) NZ732978A (es)
PL (1) PL3245224T3 (es)
PT (1) PT3245224T (es)
RU (1) RU2749712C2 (es)
WO (1) WO2016113246A1 (es)
ZA (1) ZA201704366B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY37651A (es) * 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
CN108949789A (zh) * 2018-06-26 2018-12-07 山东兴瑞生物科技有限公司 抗gcc的核酸、其制备方法、具有该核酸的免疫细胞及其应用
US20220389066A1 (en) * 2019-11-05 2022-12-08 Affibody Ab Polypeptides
CN111856029B (zh) * 2020-06-19 2023-09-26 北华大学 Il-17a蛋白在膀胱癌中的应用
AR128475A1 (es) * 2022-02-08 2024-05-15 Affibody Ab Polipéptidos y proteínas de fusión con afinidad de unión por tslp
WO2023196913A2 (en) * 2022-04-07 2023-10-12 Acelyrin, Inc. Methods of treating ankylosing spondylitis
WO2023196916A1 (en) * 2022-04-07 2023-10-12 Acelyrin, Inc. Methods of treating of hidradenitis suppurativa
CN116466095B (zh) * 2023-06-15 2023-09-01 朗肽生物制药股份有限公司 一种多肽及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0524788D0 (en) * 2005-12-05 2006-01-11 Affibody Ab Polypeptides
EP2481753B1 (en) 2005-12-13 2018-04-18 Eli Lilly and Company Anti-IL-17 Antibodies
CN104710518A (zh) 2007-07-31 2015-06-17 阿菲博迪公司 新白蛋白结合组合物、方法及应用
WO2009077175A1 (en) * 2007-12-19 2009-06-25 Affibody Ab Polypeptide derived from protein a and able to bind pdgf
RU2015132478A (ru) 2009-03-05 2015-12-10 Эббви Инк. Связывающие il-17 белки
NZ598351A (en) * 2009-08-27 2014-08-29 Covagen Ag Il-17 binding compounds and medical uses thereof
CN107686513A (zh) * 2010-03-08 2018-02-13 通用电气医疗集团生物工艺研发股份公司 免疫球蛋白G Fc区结合多肽
NZ604805A (en) 2010-07-09 2014-09-26 Affibody Ab Polypeptides
WO2012125680A1 (en) 2011-03-16 2012-09-20 Novartis Ag Methods of treating vasculitis using an il-17 binding molecule
EP2597102A1 (en) * 2011-11-25 2013-05-29 Covagen AG A novel fusion protein comprising an antibody light chain and a polypeptide binding to IL-17
KR102336895B1 (ko) * 2012-02-20 2021-12-08 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) 인간 보체 c5에 결합하는 폴리펩티드
EP2711016A1 (en) * 2012-09-21 2014-03-26 Covagen AG Novel IL-17A binding molecules and medical uses thereof
KR102123457B1 (ko) 2012-09-25 2020-06-16 애피바디 에이비 알부민 결합 폴리펩타이드
US10011641B2 (en) * 2012-10-25 2018-07-03 Affibody Ab ABD binding polypeptide
CN105190314A (zh) * 2013-01-21 2015-12-23 阿布维公司 用于炎性疾病的抗-tnf和抗-il17联合疗法生物标志物
WO2014140366A1 (en) * 2013-03-15 2014-09-18 Affibody Ab New polypeptides
WO2015091957A1 (en) 2013-12-20 2015-06-25 Affibody Ab Engineered albumin binding polypeptide

Also Published As

Publication number Publication date
PL3245224T3 (pl) 2021-01-25
EP3738976A1 (en) 2020-11-18
DK3245224T3 (da) 2020-09-21
EP3245224A1 (en) 2017-11-22
RU2017127012A (ru) 2019-02-14
EP3245224B1 (en) 2020-07-15
BR112017014559A2 (pt) 2018-05-15
HUE052121T2 (hu) 2021-04-28
IL253004B (en) 2021-06-30
US10934335B2 (en) 2021-03-02
US20170362290A1 (en) 2017-12-21
NZ732978A (en) 2022-01-28
ES2822431T3 (es) 2021-05-04
JP7208963B2 (ja) 2023-01-19
JP2023052258A (ja) 2023-04-11
KR20170116023A (ko) 2017-10-18
JP6943764B2 (ja) 2021-10-06
IL253004A0 (en) 2017-08-31
RU2017127012A3 (es) 2019-06-24
US20210253659A1 (en) 2021-08-19
AU2016208161B2 (en) 2020-01-16
ZA201704366B (en) 2022-09-28
WO2016113246A1 (en) 2016-07-21
JP2021073174A (ja) 2021-05-13
RU2749712C2 (ru) 2021-06-16
CA2972683A1 (en) 2016-07-21
JP2018508186A (ja) 2018-03-29
CN108064235A (zh) 2018-05-22
AU2016208161A1 (en) 2017-07-13
MY188784A (en) 2021-12-31
PT3245224T (pt) 2020-10-08
JP7456024B2 (ja) 2024-03-26

Similar Documents

Publication Publication Date Title
NZ732978A (en) Il-17a-binding polypeptides
MX2018005399A (es) Nuevo polipeptido con afinidad por pd-l1.
EP3957723A3 (en) Engineered ligase variants
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
ZA202100676B (en) Anti-tigit antibody and uses thereof
MY196646A (en) Agonistic Antibodies Specifically Binding Human CD40 And Methods of use
MX2018005550A (es) Anticuerpos que se unen especificamente a tim-3 y sus usos.
MX2018011503A (es) Proteinas de union y metodos de uso de las mismas.
MY198059A (en) Anti-ox40 antibodies and their uses
SG10201909716RA (en) Modified j-chain
MX2021008318A (es) Nuevos polipeptidos de union especifica y usos de los mismos.
SG10201808523RA (en) Il-22 polypeptides and il-22 fc fusion proteins and methods of use
MX2017009767A (es) Nuevas proteínas específicas para la angiogénesis.
MX2015012872A (es) Anticuerpos anti-tau y metodos de uso.
MX2017003211A (es) Anticuerpos anti-met y composiciones.
SA519402159B1 (ar) بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
MY188405A (en) Anti-cd154 antibodies and methods of using them
WO2015031778A3 (en) Compositions and methods for the treatment or prevention of tuberculosis
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
PH12016500371A1 (en) Stable polypeptides binding to human complement c5
EA201591421A1 (ru) Препараты полипептида фактора ix
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
PH12019502694A1 (en) Anti-trkb antibodies
MX2018013556A (es) Polipeptidos variantes con rendimiento mejorado y uso de los mismos.